BeOne Medicines registers Phase 1a/1b trial of RAS inhibitor BG-85738 in solid tumors
BeOne Medicines' first-in-human study of oral RAS inhibitor BG-85738 is recruiting patients with RAS-mutated advanced or metastatic solid tumors.
One new trial record for BeOne Medicines this week.
- BeOne Medicines is recruiting for a Phase 1a/1b study (NCT07746141) of BG-85738, an oral drug designed to block RAS proteins that are hyperactive1, in patients with RAS-mutated advanced or metastatic solid tumors. The study plans to enroll 100 participants, started on 2026-09-02, and will test BG-85738 alone and in combination with tislelizumab or in combination with cetuximab1, with estimated primary completion on 2028-09-30.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.